Page 48 - EFH 222

El Farmacéutico Hospitales. 2021; 222: 37-46 12. Koga YM, Akita YM, Nishioka J, Yatsuga S, Povalko N, Tanabe Y, et al. L-arginine improves the symptoms of strokelike episodes in MELAS. Neurology. 2005; 64(4): 710-712. 13. Koga Y, Povalko N, Inoue E, Nakamura H, Ishii A, Suzuki Y, et al. Therapeutic regimen of L-arginine for MELAS: 9-year, prospective, multicenter, clinical research. J Neurol. 2018; 265(12): 2.861-2.874. 14. Rodan LH, Poublanc J, Fisher JA, Sobczyk O, Mikulis DJ, Tein I. L-arginine effects on cerebrovascular reactivity, perfusion and neurovascular coupling in MELAS (mitochondrial encephalomyopathy with lactic acidosis and stroke-like episodes) syndrome. PLoS One. 2020; 15(9): e0238224. 15. El-Hattab AW, Almannai M, Scaglia F. Arginine and citrulline for the treatment of MELAS syndrome. J Inborn Errors Metab Screen. 2017; 5: 10.2326409817697399. 16. O’Ferral E. Mitochondrial myopathies: clinical features and diagnosis. En: Shefner JM, Hahn S, Dashe JF (eds.). UpToDate 2021: UpToDate Inc. Disponible en: https://www. uptodate.com/contents/mitochondrial-myopathies-clinical- features-and-diagnosis 17. Gruosso F, Montano V, Simoncini C, Siciliano G, Mancuso M. Therapeutical management and drug safety in mitochondrial diseases-Update 2020. J Clin Med. 2021; 10 (1): 94. 46 el farmacéutico hospitales n.o 222